非小细胞肺癌分期分型与血小板计数及参数的相关性分析

目的：观察非小细胞肺癌（NSCLC）患者分型分期与血小板数量和血小板参数的变化，探讨其相关性及其临床意义。方法对1507例NSCLC各期患者血小板数量和血小板数分布宽度、平均血小板体积、血小板压积进行检测并与200例健康体检者（对照组）对比分析。结果 NSCLC各期血小板增高患者比例的比较，差异有统计学意义（χ2=62.79，P＜0.05）。 NSCLCⅡ期、Ⅲ期、Ⅳ期血小板增高比例均高于Ⅰ期，差异均有统计学意义（χ2分别=41.30、49.42、56.08，P均＜0.05）。 NSCLC患者血小板数分布宽度、平均血小板体积、血小板压积与对照组比较，差异均有统计学意义（t分别=3.29、15.64、2.40， P均＜0.05）。 NSCLCⅡ期、Ⅳ期的血小板数分布宽度与对照组相比，差异有统计学意义（t分别=9.07、2.82， P均＜0.05）；NSCLCⅢ期、Ⅳ期的平均血小板体积与对照组相比，差异有统计学意义（t分别=8.39、19.67， P均＜0.05）；NSCLCⅣ期的血小板压积与对照组相比，差异有统计学意义（t=4.70，P＜0.05）。NSCLC各分期平均血小板体积、血小板宽度、血小板压积组间比较，差异均无统计学意义（F分别=1.47、1.05、0.47， P均＞0.05）。结论 NSCLC继发性血小板增多者的比例与分期有关，分期越晚比例越高。 NSCLC不同阶段血小板数量和血小板参数有一定的差异，对NSCLC的进展及预后的判断有参考价值。

NSCLC staging and pathologic classification are correlated with platelet counts and parameters

Objective To observe changes of non small cell lung cancer （NSCLC） staging and platelet counts typing （PLT） and platelet parameters and to explore its relevance and clinical significance. Methods The platelet count and the platelet count distribution width（PDW）, mean platelet volume（MPV）, platelet hematocrit （PCT） of 1507 cases of NSCLC were detected and analyzed. Results Comparing the thrombocytosis rate of different stages of NSCL patients ,the difference was statistically significant（χ2=62.79 ,P〈0.05）. The thrombocytosis rate of stage Ⅱ,Ⅲand IV were significant higher than stageⅠ （χ2=41.30,49.42,56.08, P〈0.05）. Compared with the healthy control group, the PDW, MPV, PCT of NSCLC group were significantly higher （t=3.29, 15.64, 2.40, P〈0.05）. The PDW of NSCLC stageⅡand Ⅳ were significantly higher than the healthy control group （t=9.07, 2.82, P〈0.05）. The MPV of NSCLC stageⅢ and Ⅳ were significantly higher than the healthy control group （t=8.39, 19.67, P〈0.05）. The PCT of NSCLC stageⅣwas significantly higher than the healthy control group （t=4.70, P〈0.05）. The MPV, PDW and PCT of each stage were not significantly different （F=1.47,1.05,0.47,P〉0.05）. Conclusion The proportion secondary thrombocytosis in NSCLC was related with the stage, the higher the proportion of the later stages. Different stages of lung cancer, platelet count （PLT） and platelet parameters were vary, which had reference value to judge the progression and prognosis of NSCLC.